Merck Sharpe & Dohme (UK) Limited

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

Address

, LONDON

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Merck Sharpe & Dohme (UK) Limited
Sign up free

Contracts awarded to Merck Sharpe & Dohme (UK) Limited

The contracts that Merck Sharpe & Dohme (UK) Limited have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024

Project title: NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) for the treatment of HIV (Lot 1) & For the provision of a service to supply over labelled Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) Packs for the prevention of HIV (Lot 2) 1st November 2024 Offer reference number: CM/PHS/24/5709 Period of framework agreement: 1st November 2024 to 31st October 2026 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 24 months.

£626,522,476 Bids close: 8 months ago
Award

Published 4 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 9 months ago
Award

Published 8 months ago

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Bids close: 1 year ago
Award

Published 10 months ago

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

£580,156,000 Bids close: 1 year ago

Merck Sharpe & Dohme (UK) Limited

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Merck Sharpe & Dohme (UK) Limited

NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024

NHS Branded Medicines Tranche Framework for London and South of England

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

Contacts

Statistics (1 Year)